News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
338,436 Results
Type
Article (20164)
Company Profile (129)
Press Release (318143)
Section
Business (106639)
Career Advice (880)
Deals (18840)
Drug Delivery (97)
Drug Development (51171)
Employer Resources (79)
FDA (7793)
Job Trends (7798)
News (188026)
Policy (17519)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (742)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (28459)
ALS (53)
Alzheimer's disease (639)
Antibody-drug conjugate (ADC) (88)
Approvals (7805)
Artificial intelligence (138)
Autoimmune disease (12)
Automation (4)
Bankruptcy (177)
Best Places to Work (5600)
BIOSECURE Act (13)
Biosimilars (95)
Biotechnology (57)
Bladder cancer (30)
Brain cancer (18)
Breast cancer (110)
Cancer (1029)
Cardiovascular disease (109)
Career advice (713)
Career pathing (20)
CAR-T (54)
Cell therapy (150)
Cervical cancer (5)
Clinical research (42948)
Collaboration (453)
Compensation (153)
Complete response letters (23)
COVID-19 (1104)
CRISPR (21)
C-suite (142)
Cystic fibrosis (56)
Data (1087)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (137)
Diagnostics (1879)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (75)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (57)
Earnings (39272)
Editorial (30)
Employer branding (10)
Employer resources (73)
Events (48958)
Executive appointments (422)
FDA (8360)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (308)
Gene editing (45)
Generative AI (17)
Gene therapy (144)
GLP-1 (580)
Government (1841)
Grass and pollen (2)
Guidances (18)
Healthcare (6024)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (81)
Indications (17)
Infectious disease (1182)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (24)
Intellectual property (55)
Interviews (117)
IPO (7424)
IRA (45)
Job creations (2443)
Job search strategy (649)
Kidney cancer (7)
Labor market (21)
Layoffs (275)
Leadership (14)
Legal (4195)
Liver cancer (31)
Lung cancer (154)
Lymphoma (84)
Machine learning (2)
Management (30)
Manufacturing (193)
MASH (47)
Medical device (2103)
Medtech (2106)
Mergers & acquisitions (11658)
Metabolic disorders (474)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (46)
Neuropsychiatric disorders (20)
Neuroscience (939)
NextGen: Class of 2025 (2377)
Non-profit (906)
Northern California (1049)
Now hiring (20)
Obesity (296)
Opinion (189)
Ovarian cancer (33)
Pain (66)
Pancreatic cancer (35)
Parkinson's disease (82)
Partnered (11)
Patents (130)
Patient recruitment (46)
Peanut (16)
People (33665)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13441)
Phase II (18194)
Phase III (14573)
Pipeline (684)
Podcasts (69)
Policy (104)
Postmarket research (1644)
Preclinical (4699)
Press Release (29)
Prostate cancer (59)
Psychedelics (16)
Radiopharmaceuticals (165)
Rare diseases (233)
Real estate (3227)
Recruiting (29)
Regulatory (12616)
Reports (22)
Research institute (830)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (24)
Schizophrenia (58)
Series A (58)
Series B (31)
Service/supplier (7)
Sickle cell disease (35)
Southern California (1000)
Special edition (15)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2038)
State (2)
Stomach cancer (9)
Supply chain (50)
Tariffs (14)
The Weekly (49)
United States (9841)
Vaccines (267)
Venture capitalists (27)
Webinars (11)
Weight loss (233)
Women's health (14)
Worklife (7)
Date
Last 7 days (357)
Last 30 days (1283)
Last 365 days (17054)
2025 (4373)
2024 (17818)
2023 (19861)
2022 (26564)
2021 (27333)
2020 (25383)
2019 (20319)
2018 (15746)
2017 (17517)
2016 (16453)
2015 (19124)
2014 (15031)
2013 (12749)
2012 (13733)
2011 (14026)
2010 (12914)
Location
Africa (410)
Alabama (22)
Alaska (1)
Arizona (65)
Arkansas (8)
Asia (25096)
Australia (3320)
California (2448)
Canada (1073)
China (313)
Colorado (95)
Connecticut (96)
Delaware (69)
Europe (53612)
Florida (421)
Georgia (53)
Idaho (16)
Illinois (239)
India (19)
Indiana (169)
Iowa (3)
Japan (115)
Kansas (61)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (359)
Massachusetts (2073)
Michigan (48)
Minnesota (134)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (15)
New Hampshire (8)
New Jersey (999)
New Mexico (21)
New York (715)
North Carolina (491)
North Dakota (2)
Northern California (1049)
Ohio (80)
Oklahoma (5)
Oregon (21)
Pennsylvania (576)
Puerto Rico (10)
Rhode Island (14)
South America (609)
South Carolina (3)
Southern California (1000)
Tennessee (38)
Texas (325)
Utah (53)
Virginia (79)
Washington D.C. (41)
Washington State (209)
Wisconsin (20)
338,436 Results for "audiocure pharma gmbh".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study
November 26, 2024
·
2 min read
AudioCure Pharma Receives Hearing Technology Innovator Award for its Innovative Compound AC102 for the Treatment of Sudden Hearing Loss
AudioCure Pharma GmbH announced that it has been awarded for its innovative compound AC102 by the Hearing Technology Innovator Awards™, honoring technological innovation and breakthroughs in the hearing industry.
December 7, 2023
·
2 min read
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH
March 19, 2025
·
1 min read
FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
February 7, 2024
·
3 min read
Drug Development
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need in gastrointestinal (“GI”) disorders, and European partner, Dr. Falk Pharma GmbH (“Dr. Falk Pharma”), announce U.S Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for naronapride to treat patients with gastroparesis.
March 27, 2024
·
5 min read
Government
Trump Threatens Big Pharma With Tariffs—Unless They Reshore Manufacturing: Bloomberg
President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.
February 24, 2025
·
2 min read
·
Tristan Manalac
Press Releases
T-CURX GmbH Enters into Technology Access Agreement with Kytopen
February 14, 2025
·
5 min read
Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
Renexxion Ireland Limited announced that its European Partner, Dr. Falk Pharma GmbH, has elected to advance the development of naronapride for patients with proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease as the second indication in their licensed territories.
February 7, 2024
·
5 min read
1 of 33,844
Next